Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Nowotwór, który można zmierzyć na zdjęciach i pobrać próbkę tkanki przed i podczas leczenia
- •Ogólny stan zdrowia pacjenta nie może być znacznie obciążony chorobą (skala 0-1 w ECOG)
- •Widoczny nowotwór na tomografii komputerowej lub rezonansie magnetycznym z ostatnich 3 tygodni
- •Dla raka płaskonabłonkowego skóry: wcześniejsze leczenie immunoterapią (anti-PD-1) lub nietolerancja takiego leczenia
- •Dla raka płaskonabłonkowego głowy i szyi w połączeniu z pembrolizumabem: brak wcześniejszego leczenia systemowego w zaawansowanym stadium
✗ Disqualifies
- •Wcześniejsze leczenie przeciwciałami anti-EGFR w zaawansowanym stadium choroby (dotyczy raka skóry)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 6, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (21)
Moores Cancer Center UC San Diego Health
La Jolla, United States
Keck School of Medicine of USC
Los Angeles, United States
UCLA
Los Angeles, United States
University of California, Davis Comprehensive Cancer Center
Sacramento, United States
H. Lee Moffitt Cancer Center and Research Institute, Inc
Tampa, United States
Dana Farber/Partners Cancer Care Inc
Boston, United States
Memorial Sloan Kettering
New York, United States
Columbia University Herbert Irving Comprehensive Cancer Center
New York, United States
Levine Cancer Institute
Charlotte, United States
Cleveland Clinic
Cleveland, United States
UPMC Hillman Cancer Center
Pittsburgh, United States
Rhode Island Hospital
Providence, United States
Medical University of South Carolina, Hollings Cancer Center
Charleston, United States
Vanderbilt University Medical Center
Nashville, United States
MD Anderson Cancer Center
Houston, United States
Chris O'Brien Lifehouse
Camperdown, Australia
Calvary Mater Newcastle
Waratah, Australia
Austin Hospital
Heidelberg, Australia
Peter MacCallum Cancer Centre
Melbourne, Australia
Princess Margaret Cancer Centre
Toronto, Canada
Centre hospitalier de l'Université de Montréal (CHUM)
Montreal, Canada
Trial contact
David Bohr
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.